Authors: Hamilton K R et al.
Anesthesiology, March 13, 2026, 10.1097/ALN.0000000000005925
This double-blind, randomized, placebo-controlled crossover trial evaluated whether combining an opioid with a cannabinoid improves analgesia in patients with knee osteoarthritis. Preclinical research has suggested that cannabinoids may enhance opioid analgesia, potentially allowing lower opioid doses while maintaining effective pain relief. However, high-quality human trials examining this interaction are limited.
The investigators enrolled 21 adults with symptomatic knee osteoarthritis, with a mean age of approximately 63 years. Participants completed multiple study sessions in which they received different oral drug combinations under blinded conditions. The study tested four conditions: placebo plus placebo, dronabinol (10 mg) plus placebo, hydromorphone (2 mg) plus placebo, and hydromorphone combined with dronabinol. In the first session, all participants received hydromorphone plus placebo to establish safety and baseline opioid response.
Pain outcomes were measured using both clinical pain ratings and experimentally induced pain models. Quantitative sensory testing included pressure pain thresholds, capsaicin-induced hyperalgesia, thermal pain thresholds, temporal summation, cold pressor tests, and measures of central sensitization. Additional outcomes included cognitive performance, physical function, subjective drug effects, and adverse events.
Hydromorphone demonstrated modest analgesic effects in some experimental pain measures. Specifically, it increased pressure pain thresholds and reduced sensitized mechanical temporal summation compared with placebo. These effects suggest that hydromorphone retained measurable analgesic activity in laboratory pain models.
In contrast, dronabinol did not produce significant analgesic effects across the experimental pain measures tested. Furthermore, there were no meaningful improvements in clinical pain severity across any drug condition, including the combination therapy.
Most importantly, the combination of hydromorphone and dronabinol did not produce evidence of synergistic analgesia. The combined therapy did not outperform hydromorphone alone in experimental pain outcomes. This finding directly contradicts the hypothesis suggested by many preclinical studies that cannabinoid–opioid combinations might produce additive or synergistic analgesic effects.
The study also examined cognitive and subjective drug effects. Hydromorphone impaired working memory accuracy and produced stronger “good drug effects” ratings compared with placebo. Dronabinol produced higher ratings of feeling “high” compared with hydromorphone. When the two drugs were combined, participants experienced slower working memory reaction times, greater subjective intoxication, and more nausea than hydromorphone alone.
Importantly, despite these subjective effects, the combination did not increase drug liking or adverse event severity in a statistically significant way compared with the individual agents. Physical function measures such as walking distance, stair climbing time, and Timed Up and Go performance were not significantly affected by any drug condition.
Overall, the study suggests that combining an opioid and a cannabinoid does not produce clinically meaningful analgesic synergy in knee osteoarthritis. The results challenge assumptions derived from preclinical work and highlight the need for careful clinical evaluation before adopting combination analgesic strategies.
What You Should Know
Cannabinoid–opioid combinations have been proposed as a strategy to improve analgesia while reducing opioid requirements.
This controlled trial found no evidence of synergistic pain relief when hydromorphone and dronabinol were combined.
Hydromorphone showed modest effects in laboratory pain testing but did not significantly improve clinical osteoarthritis pain.
Dronabinol produced subjective psychoactive effects but did not demonstrate meaningful analgesic benefit.
The combination increased subjective intoxication and cognitive impairment without improving pain control.
Key Points
Double-blind randomized crossover trial in 21 patients with knee osteoarthritis.
Hydromorphone modestly increased pressure pain thresholds and reduced mechanical temporal summation.
Dronabinol alone did not produce significant analgesic effects.
The hydromorphone–dronabinol combination showed no synergistic analgesia.
Combination therapy increased subjective “high” ratings and nausea without improving pain outcomes.
These findings challenge the hypothesis that opioid–cannabinoid combinations meaningfully enhance clinical analgesia.
Thank you to Anesthesiology for allowing us to summarize this article.